Sharps Technology (STSS) Q4 2025 earnings summary

Executive summary

• Transitioned from syringe manufacturing to a dual focus on medical device distribution and a digital asset treasury strategy centered on Solana (SOL), with over 2 million SOL held as of year-end 2025.

• Discontinued R&D and manufacturing, spun off Hungarian subsidiary, and settled related litigation.

• Initiated a $100M share repurchase program and completed significant equity and digital asset financings, raising over $400M in August 2025.

Financial highlights

• Reported net loss of $282.5M for 2025, driven by $152.9M unrealized losses on SOL, $101.3M warrant issuance expense, and $107.5M in stock-based compensation.

• Revenues: $204K from medical device sales and $6.8M net staking revenue from SOL.

• Cash at year-end: $10.4M; digital assets at fair value: $250.1M; working capital: $14.2M.

• Gross proceeds from August 2025 PIPE and related offerings: $411M; net proceeds: $403M.

Outlook and guidance

• Focus on expanding medical device distribution and leveraging SOL treasury for long-term growth and potential acquisitions.

• Plans to maintain high SOL exposure, generate yield through staking, and selectively use derivatives for risk management.